Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone
March 25, 2019
OBE022
Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch
Read moreSafety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor
March 18, 2019
OBE022
Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye
SRI Conference, 12-16 March 2019, Paris, France
Abstract S-001: page 299A
Abstracts. Reprod. Sci. 26, A62–A390 (2019). https://doi.org/10.1177/1933719119834079
Read moreEfficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs
January 28, 2019
OBE022
Simon Coates, Oliver Pohl, Jean-Pierre Gotteland, Jörg Täubel, Ulrike Lorch
Article first published online: January 27, 2019
Read moreOBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor
May 18, 2018
OBE022
Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, Guillaume P, Lluel P, Meen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.
Read morePharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women
April 30, 2018
OBE022
Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U
Read moreEffects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits
March 10, 2018
OBE022
Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-037: page 265A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A Abstract S-037
Read moreSafety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women
OBE022
Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-038: Pages 265A-266A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A-266A Abstract S-038
Read moreConfirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments
February 28, 2018
OBE022
Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl
Read moreConfirmation of the Cardiac Safety of OBE022 in a First in Human Study in Healthy Subjects using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity
September 19, 2017
OBE022
J. Täubel, U. Lorch , G. Ferber , O Pohl
ACCP Conference, 17-19 September 2017, San Diego, CA
Poster 019: Page 16
FP receptor antagonist, OBE002, inhibits both PGF2α- and OT-induced contractions of human pregnant myometrium in vitro
July 5, 2017
OBE022
L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou
ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract P-692: Page i452